Mark Geyer

Clinician-scientist and author discussing a phase 1 pilot study of CD371-targeted CAR T cells engineered to secrete interleukin-18 for relapsed/refractory acute myeloid leukemia, including clinical outcomes and safety.

Best podcasts with Mark Geyer

Ranked by the Snipd community

Dec 25, 2025 • 24min

Novel Treatment Targets for Hemophilia A and AML

Join researcher Vincent Muczynski, who presents a groundbreaking AAV gene therapy strategy for hemophilia A using a novel bispecific antibody. He details impressive preclinical results showing promise in correcting bleeding in mice. Clinician-scientist Mark Geyer unveils his phase 1 study on CD371-targeted CAR T cells infused with interleukin-18, which shows potential in tackling relapsed/refractory acute myeloid leukemia. Translational scientist Susan DeWolf shares insights from their analyses, revealing how interleukin-18 fosters immune remodeling and enhances treatment effectiveness.

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app